Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Pharmacotherapy may achieve diabetes remission
Last updated July 4, 2026
Key finding
4 out of 14 patients (28.57%) in the intervention arm were in remission.
This study evaluated the effectiveness of pharmacotherapy for achieving diabetes remission. It found that both intervention and control groups had patients in remission, with notable weight loss in the intervention group.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effectiveness of pharmacotherapy for achieving diabetes remission. It found that both intervention and control groups had patients in remission, with notable weight loss in the intervention group.
Clinical relevance
Achieving diabetes remission can significantly improve patients' quality of life and reduce the risk of diabetes-related complications. Understanding which pharmacotherapy options are effective can guide clinicians in providing better treatment strategies for their patients.
Keep in mind
Small sample size may limit generalizability. Short duration of follow-up may not capture long-term effects. Potential confounding factors not fully controlled.
Published in
Journal Reference
Publication details and source links for this paper.
Anand S, Durairaj A, Shobhit B, et al. Pharmacotherapy targeting tight glycaemic control is effective in achieving diabetes remission. Indian Journal of Endocrinology and Metabolism. 2025;29(2):217-223. doi:10.4103/ijem.ijem_356_24
Main Effects
28.57% of participants in the intervention arm achieved diabetes remission.
Weight loss of 4.7 kg was observed in the intervention arm.
BMI decreased by -1.58 kg/m² in the intervention arm.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Liraglutide, Dapagliflozin, and Metformin, Metformin + glimepiride and BMI, Body fat mass, Body fat percentage reduction, and 4 more.
This study contributes evidence to
Primary intervention
Liraglutide, Dapagliflozin, and Metformin
Primary outcomes
- BMI
- Body fat mass
- Body fat percentage reduction
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
14
Evidence pairs
14
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
14
Evidence pairs
281
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 14 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Metformin Therapies and Body Mass Index
Related evidence
Evidence relationship
Metformin Therapies and Body Weight
Save evidence
Evidence relationship
Metformin Therapies and Insulin Resistance
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Body fat mass
Liraglutide, Dapagliflozin, and Metformin → Body fat mass
Liraglutide, Dapagliflozin, and Metformin → Body fat mass
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerBody fat percentage reduction
Liraglutide, Dapagliflozin, and Metformin → Body fat percentage reduction
Liraglutide, Dapagliflozin, and Metformin → Body fat percentage reduction
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerBody weight
Liraglutide, Dapagliflozin, and Metformin → Body weight
Liraglutide, Dapagliflozin, and Metformin → Body weight
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerDiabetes remission
Liraglutide, Dapagliflozin, and Metformin → Diabetes remission
Liraglutide, Dapagliflozin, and Metformin → Diabetes remission
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerDisposition Index
Liraglutide, Dapagliflozin, and Metformin → Disposition Index
Liraglutide, Dapagliflozin, and Metformin → Disposition Index
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerInsulin resistance
Liraglutide, Dapagliflozin, and Metformin → Insulin resistance
Liraglutide, Dapagliflozin, and Metformin → Insulin resistance
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerBody fat percentage reduction
Metformin + glimepiride → Body fat percentage reduction
Metformin + glimepiride → Body fat percentage reduction
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerDiabetes remission
Metformin + glimepiride → Diabetes remission
Metformin + glimepiride → Diabetes remission
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerDisposition Index
Metformin + glimepiride → Disposition Index
Metformin + glimepiride → Disposition Index
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerInsulin resistance
Metformin + glimepiride → Insulin resistance
Metformin + glimepiride → Insulin resistance
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- 28.57% remission in intervention group versus 33.33% in control group.
- Weight loss of 4.7 kg in intervention group.
- BMI reduction of -1.58 kg/m² in intervention group.
Who this applies to
- Adults with type 2 diabetes.
- Patients seeking pharmacotherapy for diabetes management.
Keep in Mind
- Results may not apply to all diabetes types.
- Further research needed to confirm long-term effectiveness.
- Findings are based on a specific population with defined characteristics.
Between the Lines
- Small sample size may limit generalizability.
- Short duration of follow-up may not capture long-term effects.
- Potential confounding factors not fully controlled.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and Body Weight, Liraglutide, Dapagliflozin, and Metformin and Body Mass Index.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Metformin Therapies → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Body Weight Evidence Hub
All studies measuring Body Weight
2 studies
outcome_hubMeasures Body Weight as a key outcome.
Metformin Therapies Evidence Hub
All studies on Metformin Therapies
2 studies
intervention_hubContributes to Metformin Therapies evidence base.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
1 studies
outcome_hubMeasures Body Mass Index as a key outcome.
Liraglutide, Dapagliflozin, and Metformin Evidence Hub
All studies on Liraglutide, Dapagliflozin, and Metformin
1 studies
intervention_hubContributes to Liraglutide, Dapagliflozin, and Metformin evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Metformin + glimepiride and Body weight
Intervention: Metformin + glimepirideOutcome: Body weight
2 results
All studies on Liraglutide, Dapagliflozin, and Metformin and BMI
Intervention: Liraglutide, Dapagliflozin, and MetforminOutcome: BMI
1 results
All studies on Metformin + glimepiride
Intervention: Metformin + glimepiride
2 results
All studies on Liraglutide, Dapagliflozin, and Metformin
Intervention: Liraglutide, Dapagliflozin, and Metformin
1 results
All studies measuring Body weight
Outcome: Body weight
2 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Metformin Therapies affect body mass index?
Strong Evidence
Metformin Therapies appears to improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies affect body weight?
Strong Evidence
Metformin Therapies may improve Body Weight.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 6 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies improve insulin resistance?
Strong Evidence
Metformin Therapies may improve Insulin Resistance.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Insulin resistance
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 7 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies improve body composition?
Strong Evidence
Metformin Therapies appears to improve Body Composition.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body fat mass
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
Body fat percentage reduction
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Insulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.Low-Carbohydrate Diet Improves Weight Loss in Obese IndividualsTime-restricted diet aids glucose control in diabetesTriple Drug Combination Improves Glycemic Control in Type 2 DiabetesDietary supplements may lower diabetes risk in prediabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.